CompletedPhase 3NCT06497491

An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease

Studying Adult-onset Still disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AO GENERIUM
Principal Investigator
Oksana A. Markova, MD
JSC GENERIUM
Intervention
GNR-086(biological)
Enrollment
118 enrolled
Eligibility
18-75 years · All sexes
Timeline
20232025

Study locations (17)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06497491 on ClinicalTrials.gov

Other trials for Adult-onset Still disease

Additional recruiting or active studies for the same condition.

See all trials for Adult-onset Still disease

← Back to all trials